"Designing Growth Strategies is in our DNA"

Aspergillosis – Pipeline Review, 2019

Region : | Published Date: Upcoming | Report ID: FBI100978| Status : Pipeline



Aspergillosis is a type of infection caused by the mold Aspergillus. Majority of the population inhale spores of Aspergillus almost every day. However, people with respiratory diseases and weak immune systems are more susceptible to get affected by Aspergillus. Aspergillosis is divided into six different types, namely; allergic bronchopulmonary aspergillosis, aspergilloma, allergic aspergillus sinusitis, chronic pulmonary aspergillosis, cutaneous aspergillosis, and invasive aspergillosis. Common symptoms of aspergillosis are fever, cough, running nose, headache, chest pain, coughing up blood, and others.

Current treatment of aspergillosis includes medications and minor surgeries. Oral corticosteroids can be used for the treatment of allergic bronchopulmonary aspergillosis. Anti-fungal medications such as voriconazole and Amphotericin B are effective for the treatment of invasive pulmonary aspergillosis. Also, surgical removal of the fungal mass and embolization is done to stop bleeding in the lungs, which is common in the case of aspergilloma.

According to the Centers for Disease Control and Prevention, 1-15% of the people with cystic fibrosis are likely to develop Allergic bronchopulmonary aspergillosis. The rising prevalence of aspergillosis is increasing the need for effective drugs for the treatment for the infection. Many pharmaceutical companies and government research institutes have been focusing on developing a new treatment for aspergillosis. For instance; Scynexis, Inc. is conducting phase 2 clinical study on SCY-078 for the treatment of aspergillosis.

To get details on market share, speak to our analyst

At present, around 40% of the pipeline candidates for Aspergillosis are in phase 3 clinical stage. Majority of the studies are sponsored by academic research institutes.

Report Description

The report on ‘Aspergillosis – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Aspergillosis. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Aspergillosis.

The report on ‘Aspergillosis – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

  • A thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
  • Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
  • Overview of dormant and discontinued pipeline products
  • Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
  • Overview of the latest developments; news articles, press releases, and relevant conferences

Report Methodology

  • All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
  • Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

  • Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products for Aspergillosis
  • Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
  • Identify the focus of leading players in relation to R&D for Aspergillosis
  • Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
  • Analyze the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary


  • 2050

Healthcare Clients

We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.